VALANX Biotech secures €3 million to advance LIV-1 ADC for metastatic triple-negative breast cancer
VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured €3 million to advance its lead antibody-drug conjugate (ADC) program.